|
|
|
| Efficacy of Moxifloxacin Combined with HRZE Chemotherapy Regimen in the Treatment of Pulmonary Tuberculosis and its Impact on Serum PCT and hs-CRP Levels |
| DING Ling, LYU Heng-yi, TIAN Yan-ru |
| Xi'an Eighth Hospital,Xi'an Shaanxi 710061 |
|
|
|
|
Abstract 【Objective】 This study aimed to investigate the efficacy of moxifloxacin combined with isoniazid,rifampicin,pyrazinamide,and ethambutol (HRZE) chemotherapy regimen in the treatment of pulmonary tuberculosis and explore effects of the therapy on serum procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) levels in patients. 【Methods】 A total of 80 patients with pulmonary tuberculosis admitted to our hospital were randomly divided into an observation group and a control group,with 40 patients in each group. Both groups received HRZE anti-tuberculosis chemotherapy regimen,while the observation group received additional moxifloxacin treatment. The treatment duration for both groups was 4 months. The sputum smear conversion rate and chest CT evaluation were compared between the two groups. Additionally,the levels of PCT and hs-CRP,immune function markers [CD8+ T cells,CD4+ T cells,immunoglobulin G (IgG),immunoglobulin A (IgA)],and occurrence of adverse reactions were compared between the two groups. 【Results】 The sputum smear conversion rate in the observation group was 92.50% (37/40),significantly higher than that in the control group (75.00%,30/40) (P<0.05). The total absorption rate on chest CT in the observation group was 97.5% (39/40),which was significantly higher than that in the control group (77.50%,31/40) (P<0.05). After treatment,the serum levels of PCT and hs-CRP in both groups were significantly lower than before treatment (P<0.05),and the observation group had significantly lower levels of PCT and hs-CRP compared to the control group (P<0.05). The levels of CD4+,IgG,and IgA were significantly higher,and CD8+ level was lower in both groups after treatment compared to before treatment,with statistical significance (P<0.05). Moreover,the observation group had significantly higher levels of IgA,CD4+ and IgG and lower CD8+ level compared to the control group (P<0.05). The overall incidence of adverse reactions after treatment showed no significant difference between the two groups (P>0.05). 【Conclusion】 Moxifloxacin combined with HRZE chemotherapy regimen demonstrates significant efficacy in the treatment of pulmonary tuberculosis,effectively improves clinical outcomes,enhances patient immune capacity,and is clinically safe. Therefore,it can be widely applied in clinical practice.
|
|
Received: 06 March 2023
|
|
|
|
|
|
[1] 李鹰,王祖康,魏尤良,等.初治涂阳肺结核患者治愈后的随访观察及复发情况的影响因素分析[J].中国全科医学,2021,24(14):1785-1789.
[2] 卢映宏,史文佩,胡屹,等.肺结核患者与健康人群肠道菌群差异及其生物标志物的比较研究[J].中华结核和呼吸杂志,2021,44(11):939-946.
[3] 董文雅,魏文静,谭卫国,等.常规抗结核化疗对肺结核患者痰液菌群的影响[J].实用医学杂志,2021,37(3):336-342.
[4] 郭武,田霞,任伟,等.莫西沙星联合纤维支气管镜药物灌注对耐多药肺结核患者T细胞亚群、肺功能和肝功能的影响[J].现代生物医学进展,2021,21(8):1541-1544.
[5] 中华医学会结核病学分会. 肺结核诊断和治疗指南[J].中国实用乡村医生杂志,2013,20(2):7-11.
[6] 殷雨天,张靓,张越,等.结核分枝杆菌痰培养阳性肺结核患者对一线抗结核药耐多药情况分析[J].吉林大学学报(医学版),2015,41(5):1080-1084.
[7] 赵婷,孙长峰,肖科,等.肺结核患者合并其他病原菌肺部感染的临床特点及危险因素分析[J].中国感染与化疗杂志,2020,20(3):249-254.
[8] 牛俊梅,李振魁,崔俊伟,等.肺结核患者住院期间获得性肺部多药耐药菌感染及其影响因素[J].中华医院感染学杂志,2020,30(12):1822-1825.
[9] 戴英增,崔勇.左氧氟沙星与莫西沙星治疗耐多药肺结核的效果和对患者住院时间的影响[J].沈阳药科大学学报,2021,38(2):27-29.
[10] 方坚,廖亮,杜培.莫西沙星与左氧氟沙星联合用药方案治疗耐多药肺结核疗效研究[J].海南医学,2020,31(15):1948-1950.
[11] 吕俊宏,彭盘俐,林少欢,等.血清PCT、CRP与s TREM-1在肺癌患者术后肺部感染中表达及其诊断价值分析[J].现代生物医学进展,2020,20(9):1711-1715.
[12] 黄晴.百合固金汤中药联合莫西沙星对耐多药肺结核患者免疫指标、T细胞亚群及肺功能指标的影响[J].辽宁中医杂志,2020,47(8):124-126.
[13] 顾贝欣,吴建博,周海峰,等.莫西沙星注射剂在老年患者中的合理性及安全性评价[J].中国医院药学杂志,2020,40(10):1150-1153. |
|
|
|
2023, Vol. 40 
